Pachmann et al., 2011 - Google Patents
Assessing the efficacy of targeted therapy using circulating epithelial tumor cells (CETC): the example of SERM therapy monitoring as a unique tool to individualize …Pachmann et al., 2011
View HTML- Document ID
- 3078182440978149709
- Author
- Pachmann K
- Camara O
- Kohlhase A
- Rabenstein C
- Kroll T
- Runnebaum I
- Hoeffken K
- Publication year
- Publication venue
- Journal of cancer research and clinical oncology
External Links
Snippet
Purpose In malignant tumors, predictive markers have been developed with respect to targeted therapies. One of the first targeted therapies was the hormone-blocking treatment of tumors of the male and female reproductive system. A typical therapy in breast cancer is the …
- 238000002560 therapeutic procedure 0 title abstract description 31
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/574—Immunoassay; Biospecific binding assay for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/574—Immunoassay; Biospecific binding assay for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Hybridisation probes
- C12Q1/6883—Hybridisation probes for diseases caused by alterations of genetic material
- C12Q1/6886—Hybridisation probes for diseases caused by alterations of genetic material for cancer
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Pachmann et al. | Assessing the efficacy of targeted therapy using circulating epithelial tumor cells (CETC): the example of SERM therapy monitoring as a unique tool to individualize therapy | |
| Vos et al. | Neoadjuvant immunotherapy with nivolumab and ipilimumab induces major pathological responses in patients with head and neck squamous cell carcinoma | |
| Eyre et al. | Microenvironmental IL1β promotes breast cancer metastatic colonisation in the bone via activation of Wnt signalling | |
| Ahmed et al. | PD-L1 protein expression on both tumor cells and macrophages are associated with response to neoadjuvant durvalumab with chemotherapy in triple-negative breast cancer | |
| Bidard et al. | Single circulating tumor cell detection and overall survival in nonmetastatic breast cancer | |
| Ignatiadis et al. | HER2-positive circulating tumor cells in breast cancer | |
| Azim Jr et al. | RANK-ligand (RANKL) expression in young breast cancer patients and during pregnancy | |
| Naume et al. | Clinical outcome with correlation to disseminated tumor cell (DTC) status after DTC-guided secondary adjuvant treatment with docetaxel in early breast cancer | |
| Koutras et al. | Vascular endothelial growth factor polymorphisms and clinical outcome in colorectal cancer patients treated with irinotecan-based chemotherapy and bevacizumab | |
| Balermpas et al. | Head and neck cancer relapse after chemoradiotherapy correlates with CD163+ macrophages in primary tumour and CD11b+ myeloid cells in recurrences | |
| Colleoni et al. | Outcome of special types of luminal breast cancer | |
| Smerage et al. | The measurement and therapeutic implications of circulating tumour cells in breast cancer | |
| Idirisinghe et al. | Hormone receptor and c-ERBB2 status in distant metastatic and locally recurrent breast cancer: pathologic correlations and clinical significance | |
| Cheng et al. | A high-throughput proteomic approach provides distinct signatures for thyroid cancer behavior | |
| Hang et al. | Prognostic value of the stem cell markers CD133 and ABCG2 expression in esophageal squamous cell carcinoma | |
| Ignatiadis et al. | Liquid biopsy-based clinical research in early breast cancer: The EORTC 90091-10093 Treat CTC trial | |
| Ahn et al. | Are there any ethnic differences in molecular predictors of erlotinib efficacy in advanced non-small cell lung cancer? | |
| Koh et al. | Expression of Lewis X is associated with poor prognosis in triple-negative breast cancer | |
| Di Cosimo et al. | Moving HER2-low breast cancer predictive and prognostic data from clinical trials into the real world | |
| Sun et al. | Expression of CPEB4 in invasive ductal breast carcinoma and its prognostic significance | |
| Wakeham et al. | Multicentre investigation of prognostic factors incorporating p16 and tumour infiltrating lymphocytes for anal cancer after chemoradiotherapy | |
| Xu et al. | Nadir CA-125 level as prognosis indicator of high-grade serous ovarian cancer | |
| Hadoux et al. | Prognostic factors of metastatic neuroendocrine carcinoma under first-line treatment with platinum etoposide with a focus on NEC score and Rb expression: Results from the multicentre RBNEC study of the Groupe d’Etude des Tumeurs Endocrines (GTE) and the ENDOCAN-RENATEN network | |
| Wang et al. | Immunohistochemical HER2 score correlates with response to neoadjuvant chemotherapy in HER2-positive primary breast cancer | |
| Gwark et al. | Analysis of the serial circulating tumor cell count during neoadjuvant chemotherapy in breast cancer patients |